Related Experiment Video
Updated: Nov 14, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel
Weihang Li1, Bin Yuan1,2, Yingjing Zhao3
1Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Abstract:
This study aimed to identify effective targets for carcinogenesis of primary myelofibrosis (PMF), as well as to screen ideal lead compounds with potential inhibition effect on Janus kinase 2 to contribute to the medication design and development. Gene expression profiles of GSE26049, GSE53482, GSE61629 were obtained from the Gene Expression Omnibus database. The differentially expressed genes were identified, and functional enrichment analyses such as Gene Ontology, protein-protein interaction network etc., were performed step by step. Subsequently, highly-precise computational techniques were conducted to identify potential inhibitors of JAK2. A series of structural biology methods including virtual screening, ADMET (absorption, distribution, metabolism, excretion, and toxicity) prediction, molecule docking, molecular dynamics simulation etc., were implemented to discover novel natural compounds. Results elucidated that PMF patients had abnormal LCN2, JAK2, MMP8, CAMP, DEFA4, LTF, MPO, HBD, STAT4, EBF1 mRNA expression compared to normal patients. Functional enrichment analysis revealed that these genes were mainly enriched in erythrocyte differentiation, neutrophil degranulation and killing cells of other organisms. Two novel natural compounds, ZINC000013513540 and ZINC000004099068 were found binding to JAK2 with favorable interaction energy together with high binding affinity. They were predicted with non-Ames mutagenicity, low-rodent carcinogenicity, less developmental toxicity potential as well as non-toxicity with liver. Molecular dynamics simulation demonstrated that these two complexes: ZINC000013513540-JAK2 and ZINC000004099068-JAK2 could exist stably under natural circumstances. In conclusion, this study revealed hub genes in the carcinogenesis of PMF. ZINC000013513540 and ZINC000004099068 were promising drugs in dealing with PMF. This study may also accelerate exploration of new drugs.
Insights
Researchers identified key genes in primary myelofibrosis (PMF) carcinogenesis and discovered two novel natural compounds that inhibit Janus kinase 2 (JAK2), offering potential new treatments for PMF.
Area of Science:
- Genomics and Bioinformatics
- Computational Chemistry
- Pharmacology
Background:
- Primary myelofibrosis (PMF) is a serious myeloproliferative neoplasm characterized by bone marrow fibrosis.
- Identifying novel therapeutic targets and lead compounds is crucial for developing effective PMF treatments.
- Janus kinase 2 (JAK2) is a key signaling protein implicated in PMF pathogenesis.
Purpose of the Study:
- To identify critical genes involved in PMF carcinogenesis.
- To screen for natural compounds that inhibit JAK2 activity.
- To provide potential drug candidates for PMF treatment development.
Main Methods:
- Analysis of gene expression profiles from the Gene Expression Omnibus database.
- Functional enrichment analyses (Gene Ontology, protein-protein interaction networks).
- Computational drug discovery including virtual screening, ADMET prediction, molecular docking, and molecular dynamics simulation.
Main Results:
- Identified abnormal mRNA expression of LCN2, JAK2, MMP8, CAMP, DEFA4, LTF, MPO, HBD, STAT4, and EBF1 in PMF patients.
- Functional enrichment analysis linked these genes to erythrocyte differentiation and neutrophil functions.
- Discovered two novel natural compounds (ZINC000013513540, ZINC000004099068) with high binding affinity to JAK2 and favorable safety profiles.
Conclusions:
- This study identified key genes in PMF carcinogenesis and potential therapeutic targets.
- The natural compounds ZINC000013513540 and ZINC000004099068 show promise as novel drugs for PMF.
- These findings may accelerate the development of new pharmacological interventions for PMF.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:16TGF - β Signaling Pathway
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:22PI3K/mTOR/AKT Signaling Pathway
02:24Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
01:15Differentiation of Common Myeloid Progenitor Cells